First Light Diagnostics offers the MultiPath platform, a benchtop analyzer that performs culture‑free microbiology testing directly from patient specimens. It delivers pathogen identification in about 30 minutes and phenotypic antimicrobial susceptibility results within four hours, with an automated sample‑to‑answer workflow and HL7/FHIR integration for clinical laboratories and stewardship programs.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BAFounders
Product
Problem
Conventional microbiology relies on culture-based methods that require 24–72 hours to identify pathogens and determine antimicrobial susceptibility, delaying targeted therapy and contributing to suboptimal antibiotic use.
Solution
First Light Diagnostics’ MultiPath platform delivers culture‑free microbiology testing by directly analyzing patient specimens. The benchtop analyzer generates pathogen identification results in approximately 30 minutes and phenotypic antimicrobial susceptibility data within four hours, eliminating the need for a growth step. Automated sample‑to‑answer workflow provides clinicians with actionable ID/AST information at the onset of infection, supporting timely therapeutic decisions and antibiotic‑stewardship initiatives. Results are securely stored and can be exported to laboratory information systems for seamless integration into existing clinical workflows.
Features
- Integrated, cartridge‑based sample preparation that processes raw specimens without a culture step
- Rapid molecular/phenotypic assay delivering pathogen ID in ~30 minutes and AST in ~4 hours
- Bench‑top footprint with a user‑friendly touchscreen interface for point‑of‑care deployment
- Automated data capture and secure cloud‑enabled storage, compatible with standard LIS/EHR interfaces via HL7/FHIR APIs
- Real‑time antimicrobial‑stewardship reporting, including susceptibility breakpoints and therapy recommendations
- Proprietary microfluidic and imaging technology that provides quantitative phenotypic susceptibility profiles directly from patient samples